AGC Pharma Chemicals’
End-to-End HPAPI Solutions

Scaling OEB 5 HPAPIs: Eliminate Containment Failures and Costly Regulatory Delays

Handling compounds with occupational exposure limits below 0.1 µg/m³ leaves zero margin for error. A single containment breach, cleaning validation setback, or tech transfer failure can derail clinical timelines and burn millions in regulatory delays. Download the technical white paper from AGC Pharma Chemicals, a specialized CDMO for Small Molecule APIs and HPAPIs, to de-risk your potent pipeline from early clinical phases to commercial-scale production

Download the Technical White Paper

Developed for CMC Leads, Chemical R&D Directors, and Pharma Operations Executives.

The Line Between Clinical Success and Manufacturing Bottlenecks

Rising demand for high-potency oncology and rare disease treatments is pushing standard CDMO infrastructure past its breaking point. Inside this technical report:

  • OEB 5 Containment Without Sacrificing Throughput:Engineering isolators and closed systems for OEL ≤0.1 µg/m³ that guarantee operator protection without killing cycle times.
  • Scale-Up & Cross-Contamination Control:Proven strategies to transition potent molecules from grams to metric tons while clearing cleaning validation thresholds on the first run.
  • FDA & EMA Inspection Red Flags:The most critical facility design and HVAC/environmental control missteps that trigger audit findings in HPAPI suites.
  • The Cost of Vendor Fragmentation:Why splitting process development and commercial manufacturing across multiple CDMOs introduces critical tech transfer risks.